首页 | 本学科首页   官方微博 | 高级检索  
检索        

凌丹康复方配合DC-CIK治疗白血病临床观察
引用本文:刘清池,吴维海,李刚荣,胡晓东,冯新旺,梁春耕,武大勇,张玉娜,庞宇慧,王荣孝,李建英,马传宝,张慧敏,牛景月.凌丹康复方配合DC-CIK治疗白血病临床观察[J].中国中西医结合杂志,2009,29(4):347-350.
作者姓名:刘清池  吴维海  李刚荣  胡晓东  冯新旺  梁春耕  武大勇  张玉娜  庞宇慧  王荣孝  李建英  马传宝  张慧敏  牛景月
作者单位:河北省石家庄平安医院,石家庄,050021
摘    要:目的 观察中药凌丹康复方配合树突状细胞联合细胞因子诱导的杀伤细胞(DC CIK) 治疗白血病的临床效果和安全性。

关 键 词:白血病  免疫治疗  树突状细胞  杀伤细胞/细胞因子诱导  中药

Effect of Lingdankang Composite Combined Dendritic Cell-Cytokine Induced Killer Cells in Treating Leukemia
Authors:LIU Qing-chi  WU Wei-hai  LI Gang-rong
Institution:LIU Qing-chi, WU Wei-hai, LI Gang-rong, et al (Department of Hematology, Ping'an Hospital, Shijiazhuang ( 050021))
Abstract:Objective To evaluate the effect and safety of Chinese herbal medicine Lingdankang Composite (LDK) combined dendritic cell-cytokine induced killer cells (DC-CIK) in treating leukemia. Methods Subjects were selected from leukemia patients who achieved hematological complete remission (HCR) but not achieved molecular biological remission (MBR), or with minimal residual leukemia (MRL) positive. Twenty patients, 19 of acute leukemia and 1 of chronic myelocytic leukemia, were enrolled. DC and CIK from patient's peripheral blood monocyte were separated respectively by blood cell separator, then DC-CIK was obtained through respective culture followed with mixed cultivation of them, and was infused back to the patient self via intravenous injection. The back infusion of DC-CIK was performed once every 15-20 days for 4-6 times in total. Meantime, LDK was administered orally every day. Results In the 20 patients treated, 4 case of HCR achieved MBR, the negatively reversed marker gene was AML1/ETO in 1 case, CBFβ/MYH11 in 1, bcr/abl in 1, and the other 1 was IgH gene rearrangement; 3 patients with positive MRL were reversed to negative. The 3-year CR rate was 75% with a medium CR period of 25 months (10-37 months). Except transient fever and chill in 5 cases, no other remarkable adverse reaction happened during or after DC-CIK infusion. Conclusion The combined treatment of LDK and autologous DC-CIK in treating patients with HCR shows an obvious effect of clearing MRL, it is the appropriate choice for curing leukemia of HCR, and is safety for intravenous infusion, so it has potential clinical prospect.
Keywords:leukemia  immunotherapy  dendritic cell  cytokine induced killer cells  Chinese herbs
本文献已被 维普 万方数据 等数据库收录!
点击此处可从《中国中西医结合杂志》浏览原始摘要信息
点击此处可从《中国中西医结合杂志》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号